|
Jul 29
|
AstraZeneca Stock Rises as US, Cancer Drugs Growth Lifts Q2 Results
|
|
Jul 29
|
AZN Q2 Earnings Meet Estimates, Sales Beat as Key Drugs Outperform
|
|
Jul 29
|
Cancer drug demand drives higher sales for AstraZeneca
|
|
Jul 29
|
AstraZeneca results: H1 and Q2 2025
|
|
Jul 29
|
Health Care Roundup: Market Talk
|
|
Jul 29
|
AstraZeneca beats profit forecasts on strong sales and U.S. demand
|
|
Jul 29
|
Astrazeneca: Q2 Earnings Snapshot
|
|
Jul 29
|
AstraZeneca Books Record Quarterly Revenue as U.S, Oncology Boosts Growth
|
|
Jul 29
|
Trending tickers: Nvidia, Sarepta, Spotify, AstraZeneca and Greggs
|
|
Jul 29
|
AstraZeneca seeks US drug price cuts amid expansion plans, strong demand
|
|
Jul 29
|
AstraZeneca PLC (AZN) Announced Positive Results for its Phase 3 Trial of Gefurulimab
|
|
Jul 28
|
Sector Update: Health Care Stocks Softer Monday Afternoon
|
|
Jul 28
|
Astrazeneca, Other US-Listed Pharma Companies Seen Insulated From New EU Tariff Deal, Barclays Says
|
|
Jul 28
|
AIM ImmunoTech Reports Positive Mid-year Safety and Efficacy Data from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
|
|
Jul 28
|
IMFINZI® (durvalumab) granted Priority Review and Breakthrough Therapy Designation in the US for patients with resectable early-stage gastric and gastroesophageal junction cancers
|
|
Jul 28
|
Trending tickers: Palantir, Samsung, Heineken, Volkswagen and AstraZeneca
|
|
Jul 25
|
AstraZeneca (LSE:AZN) Showcases Promising Results For Gefurulimab In Global Myasthenia Gravis Study
|
|
Jul 25
|
Stocks to watch next week: Microsoft, Apple, Shell, AstraZeneca and HSBC
|
|
Jul 25
|
Bristol Myers shuffles its executive ranks with new CMO
|
|
Jul 24
|
gMG race hots up as AstraZeneca’s star candidate meets Phase III targets
|